Atlas Trials

Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.

Clinical trial NCT03647878 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03647878
Sponsor
Ipsen
Status
ACTIVE_NOT_RECRUITING
Study type
OBSERVATIONAL
Advanced Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
Start date
2018-09-24
Primary completion
2027-09-30
Enrollment
224

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.